WHAT IS PERSONALIZED MEDICINE?
Personalized medicine is a fast-growing, evolving approach to health care in which physicians use information from diagnostic tests, along with a patient’s medical history, to guide prevention and treatment plans that are consistent with the patient’s biology, values, and circumstances.

WHY IS PERSONALIZED MEDICINE IMPORTANT?
The use of personalized medicine is intended to address a problem many have long recognized — treatment and prevention strategies that help some patients are less effective for others, and some medicines may cause side effects or adverse reactions in certain patients. Certain people may be more susceptible to particular conditions than others. All of this may be due to genetic or environmental factors, or both. Personalized medicine allows us to better understand and account for these factors.

Molecular Diagnostics
Molecular diagnostics — many of which are genetic — help physicians target treatments for many types of diseases to only those patients whose biological characteristics make them most likely to benefit.

Personalized Treatments
Molecularly guided treatments address the root causes of rare diseases, counteract the genetic drivers of certain types of cancers, and help patients with common and infectious diseases identify which of many treatment options are most likely to work for them.

THE CONGRESSIONAL PERSONALIZED MEDICINE CAUCUS
As part of its mission in education and advocacy, the Personalized Medicine Coalition proactively educates Members of Congress about the goals of the Congressional Personalized Medicine Caucus, which convenes a bipartisan group of Members interested in improving health care through personalized medicine. The following content includes information PMC has developed about the benefits of personalized medicine as well as the Coalition’s summary of the purpose and potential of the caucus.
WHY SHOULD YOUR MEMBER JOIN THE CAUCUS?

1. The caucus is the only forum beyond the committees of jurisdiction to collectively discuss policies for advancing personalized medicine across diseases and conditions.
2. By resolving policy issues, caucus members will help deliver better health care to their constituents.
3. Caucus members will support jobs in the health care industry that play a key role in research, innovation, and health care delivery for personalized medicine.

HOW DOES THE CAUCUS ADVANCE PERSONALIZED MEDICINE?

Personalized medicine creates the opportunity to make health care safer, fairer, and more efficient; however, ongoing challenges related to regulatory oversight and clinical adoption are making it difficult for our health care system to capitalize on this opportunity. Realizing the full potential of personalized medicine will require policymakers to support a paradigm shift from population-based to individualized health care and to understand the science that is driving progress in personalized medicine.

The Caucus Will Seek to:

- **SHAPE** legislation that encourages increased research, development, innovation, and access to personalized medicine (e.g., Cures 2.0, FDA user fee reauthorization)
- **EDUCATE** policymakers on the health and economic benefits of personalized medicine (e.g., early detection and prevention, personalized approaches to COVID-19)
- **PROMOTE** discussions about policies that encourage investment in personalized medicine (e.g., through education, reimbursement, clinical adoption, and appropriations)
- **EXPLORE** opportunities to adapt the health care system in ways that facilitate patient access to personalized medicine (e.g., novel and value-based payment mechanisms).

WHO ARE THE CAUCUS CO-CHAIRS?

The Caucus Co-chairs Include:

- Sen. Kyrsten Sinema (D-AZ)
- Sen. Tim Scott (R-SC)
- Rep. Eric Swalwell (D-CA)
- Rep. Tom Emmer (R-MN)

Members of the Personalized Medicine Coalition

The nonprofit Personalized Medicine Coalition is in support of the mission of the Congressional Personalized Medicine Caucus. The shift toward personalized medicine is widely supported by PMC’s members, who include providers, patients, researchers, and industry representatives.

Members of the Personalized Medicine Coalition

<table>
<thead>
<tr>
<th>Percentage</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>24%</td>
<td>Research, Education &amp; Clinical Care Institutions (e.g., American Association for Cancer Research; Mayo Clinic)</td>
</tr>
<tr>
<td>21%</td>
<td>Strategic Partners</td>
</tr>
<tr>
<td>15%</td>
<td>Diagnostic Companies</td>
</tr>
<tr>
<td>13%</td>
<td>Patient Advocacy Groups (e.g., Alzheimer’s Foundation of America; National Alliance for Hispanic Health)</td>
</tr>
<tr>
<td>9%</td>
<td>Large Biotech/Pharmaceutical Companies</td>
</tr>
<tr>
<td>6%</td>
<td>IT/Informatics Companies</td>
</tr>
<tr>
<td>4%</td>
<td>Emerging Biotech/Pharmaceutical Companies</td>
</tr>
<tr>
<td>3%</td>
<td>Personalized Medicine Service Providers</td>
</tr>
<tr>
<td>2%</td>
<td>Industry &amp; Trade Associations (e.g., American Medical Association)</td>
</tr>
<tr>
<td>2%</td>
<td>Clinical Laboratory Testing Services</td>
</tr>
<tr>
<td>1%</td>
<td>Research Tool Companies</td>
</tr>
<tr>
<td>&lt;1%</td>
<td>Health Insurance Companies</td>
</tr>
</tbody>
</table>

FOR MORE INFORMATION

Please visit [www.PersonalizedMedicineCoalition.org](http://www.PersonalizedMedicineCoalition.org) or email Cynthia A. Bens, Senior Vice President, Public Policy, at CBens@PersonalizedMedicineCoalition.org.

---